FDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma MultiformeGlobeNewsWire • 03/02/23
Genenta Science and AGC Biologics Enter Development and Manufacturing Service AgreementGlobeNewsWire • 02/07/23
Genenta Update at SITC22 Indicates Potential for Anti-Tumor Immune System Reset after Temferon™ Treatment in Glioblastoma PatientsGlobeNewsWire • 11/07/22
Genenta to Present at Upcoming Scientific Congresses ASGCT, BTM, ASCO and EHAGlobeNewsWire • 05/13/22
Genenta Progresses to Higher Dosing Cohort in Temferon™ Phase 1/2a Clinical Trial in Glioblastoma MultiformeGlobeNewsWire • 05/04/22
Genenta ASGCT Clinical Data Highlights Temferon™ Biological Effects in GlioblastomaGlobeNewsWire • 05/02/22
Genenta to Host Expert Fireside Chat on Immuno Gene & Cell Therapy for Treatment of Solid TumorsGlobeNewsWire • 04/20/22
Genenta Data Presentation at AACR to Describe On-Target Biological Activity of Temferon™ in Unmethylated Glioblastoma MultiformeGlobeNewsWire • 03/09/22
Genenta Closes Its Upsized Initial Public Offering of American Depository SharesGlobeNewsWire • 12/17/21